{"entity":{"id":"lm-299","kind":"drug","name":"LM-299","aka":["MK-2010"],"tldr":"LM-299 is an experimental antibody that blocks two things at once: PD-1, a brake on the immune system, and VEGF, which feeds tumour blood vessels. LaNova Medicines discovered it and Merck licensed it in 2024, where it is called MK-2010.","summary":"LM-299 is a bispecific antibody made of an anti-VEGF antibody linked to two C-terminal single-domain anti-PD-1 antibodies, designed to inhibit both PD-1/PD-L1 and VEGF/VEGFR signalling. Merck & Co. announced an exclusive global licence from LaNova Medicines on 14 November 2024, with a USD 588 million payment due at closing; a phase 1 trial was then enrolling in China. LaNova's phase 1/2 trial (NCT06650566) started in October 2024 in advanced solid tumours. ClinicalTrials.gov lists LM-299 as another name for Merck's MK-2010, which Merck is testing in phase 2 trials in advanced solid tumours, alone or with other treatments (NCT07793942) and with sacituzumab tirumotecan (NCT07785609). No results are recorded here.","status":"phase-2","asOf":"2026-11-03","links":[{"label":"Merck licence announcement, 14 November 2024","url":"https://www.merck.com/news/merck-enters-into-exclusive-global-license-for-lm-299-an-investigational-anti-pd-1-vegf-bispecific-antibody-from-lanova-medicines-ltd/"},{"label":"ClinicalTrials.gov: LM-299 phase 1/2 (NCT06650566)","url":"https://clinicaltrials.gov/study/NCT06650566"},{"label":"ClinicalTrials.gov: MK-2010 phase 2 (NCT07793942)","url":"https://clinicaltrials.gov/study/NCT07793942"},{"label":"ClinicalTrials.gov: MK-2010 with sacituzumab tirumotecan (NCT07785609)","url":"https://clinicaltrials.gov/study/NCT07785609"}],"tags":["pipeline","deal-asset"],"related":[],"cancers":[],"sections":[],"technologies":["bispecific-antibody"],"targets":["pd1","vegf"],"drugs":[],"companies":["lanova-medicines","merck"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06650566"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit (ClinicalTrials.gov v2 + company press releases)","editedOn":"2026-11-03"},"code":"MK-2010","modality":"Bispecific antibody (PD-1 x VEGF)","mechanism":"An antibody against VEGF joined to two small single-domain antibodies against PD-1. It is designed to release the PD-1 brake on immune cells and, at the same time, block the VEGF signal that tumours use to grow new blood vessels.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/lm-299/","neighbours":{"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"},{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/"}],"company":[{"id":"lanova-medicines","kind":"company","name":"LaNova Medicines","route":"/companies/lanova-medicines/"},{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}],"trial":[{"id":"nct06650566","kind":"trial","name":"Study of LM-299 in Subjects Advanced Malignant Tumors","route":"/trials/nct06650566/"}]}}